Introduction
============

Thoracic esophageal squamous cell carcinoma (ESCC) consists of \>90% of the esophageal cancer cases in East Asia, and tumors located in the upper and middle thoracic esophagus (Mt) are most commonly observed. Surgery is still a preferred therapeutic strategy for patients with thoracic ESCC. However, the recurrence rate of ESCC is as high as 50% after radical surgery during the follow-up period,[@b1-cmar-10-217] and locoregional recurrence (especially single-station lymph node recurrence) is the major cause of treatment failure,[@b2-cmar-10-217],[@b3-cmar-10-217] which correlated with an unfavorable prognosis.

At present, chemoradiotherapy (CRT) is the main treatment method for the patients with secondary lymph node metastasis (LNM) after esophagectomy; however, the therapeutic effect has not been obviously improved, and this phenomenon may be related to the gross tumor volume (GTV) of metastatic lymph nodes (V~LN~) and maximum diameter of metastatic lymph nodes (D~LN~). It is generally recognized that the high tumor burden is correlated with poor sensitivity of CRT, and the long-term prognosis is inferior. Chen et al[@b4-cmar-10-217] reported that GTV defined on radiotherapy (RT) planning scans may serve as a good prognostic factor for ESCC patients treated with radical RT; however, the prognostic value of the patients with postoperative nodal recurrences who underwent RT or CRT remains unclear.

Recently, some trials reported a close relationship between systemic hematological markers and prognosis in human malignancies,[@b5-cmar-10-217]--[@b9-cmar-10-217] and the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have been studied in various malignancies.[@b10-cmar-10-217]--[@b15-cmar-10-217] These markers, which can be measured easily and inexpensively, are widely used in clinical practice and may contribute to predict an unfavorable prognosis in patients with esophageal carcinoma.[@b10-cmar-10-217],[@b16-cmar-10-217],[@b17-cmar-10-217] This correlation has been well documented in other types of human malignancies, but the combination of tumor burden markers, which are represented by GTV and maximum diameter, and hematological markers has rarely been studied in patients with LNM after resection of ESCC. Therefore, the purpose of this study was to clarify whether pretreatment tumor burden-related index and inflammatory markers, including V~LN,~ D~LN~, NLR, and PLR, were useful for assessing the therapeutic effects and prognosis with LNM receiving CRT or radiation (RT) alone after resection of ESCC.

Patients and methods
====================

Patients
--------

Between January 2011 and December 2014, a total of 119 esophageal carcinoma patients with secondary LNM after resection of ESCC at the Department of Thoracic Surgery, the Affiliated Taixing People's Hospital of Yangzhou University were recruited in this retrospective study. The inclusion criteria were as follows: 1) secondary LNM after curative esophagectomy; 2) the diagnosis of LNM was performed by pathologic conformation or short axis of ≥10 mm in mediastinum and cervix or short axis of ≥5 mm in tracheoesophageal groove with enhanced computed tomography (CT) imaging; 3) normal liver and renal function, without severe dysfunction of important organs, and overall performance status of 0 or 1; 4) complete record of pretreatment hematological variables; 5) no presence of distant metastasis; 6) the patients with complete follow-up time ≥1 year; 7) no presence of infection or inflammatory conditions, such as rheumatologic conditions, connective tissue disorders, or heart diseases. Finally, 119 patients were enrolled and analyzed in this study. Clinicopathological features were obtained from the patients' records. This research was approved by the ethics committee of the Affiliated Taixing People's Hospital of Yangzhou University. Informed consent was obtained from all individual participants included in this study.

Treatment modalities
--------------------

All patients were treated with three-dimensional conformal RT (3-DCRT). Definitive RT alone (n=32) or in combination with chemotherapy (n=87) was intended to be administered. All treatments were planned based on CT simulation planning system with 4 mm thickness scan slice throughout the entire neck and thorax. A total dose of up to 60.0--64.0 Gy was delivered by standard fractionated RT in 30--32 fractions (2.0 Gy per fraction; over 6--7 weeks). Concurrent chemotherapy consisted of a daily dose of cisplatin (25 mg/m^2^, days 1--4) with Paclitaxel (135--175 mg/m^2^, day1) for 28 days per cycle, for a total of two cycles.

The target volumes were defined as follows: 1) GTV: metastatic lymph node; 2) clinical target volume (CTV): GTV +2 cm margins in the metastatic lymph node long axis, superiorly and inferiorly to encompass potential invasions; and 3) planning target volume (PTV): CTV +0.5 cm margin.

Assessment of therapeutic effect
--------------------------------

Clinical responses were assessed by CT scan 1 month after RT with or without two cycles of chemotherapy. Tumor response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1).[@b18-cmar-10-217] Accordingly, tumor response was divided into four groups as follows: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Patients demonstrating CR or PR after treatment were defined as responders, whereas those exhibiting SD or PD were classified as non-responders.

Data collection and follow-up
-----------------------------

Images were retrieved from the patients' database, and the GTV and maximum diameter of metastatic lymph nodes (V~LN~ and D~LN~) were calculated using the Monaco 5.1 system for each patient.

The following pretreatment hematological parameters were collected within 1 week prior to the initial treatment: neutrophil count, lymphocyte count, monocyte count, and platelet count. The NLR and PLR were calculated by division of the absolute values of the corresponding hematological parameters.

After the completion of treatment, all patients were asked to return to the hospital for examination every 3 months for the first year, every 6 months for the next 2 years, and then annually. The duration of follow-up was calculated from the day of treatment to the day of death or July 2017.

Statistical analysis
--------------------

V~LN~, D~LN~, NLR, and PLR were divided into high/low group by the corresponding median value. Univariate logistic analysis was performed to determine which variables were associated with response to therapy. Variables generating *P*-values ≤ 0.05 by univariate logistic analysis were subjected to multivariate logistic regression analysis.

The overall survival (OS) curves based on pretreatment V~LN~, D~LN~, NLR, and LMR were plotted using the Kaplan--Meier method, and differences were assessed by the log-rank test. Univariate and multivariate analyses of Cox regression proportional hazard model were used to evaluate the influence of each variable on OS with the enter method. Hazard ratio (HR) with 95% confidence interval (CI) was used to quantify the strength of the association between predictors and survival. ROC curves were also plotted to verify the accuracy of V~LN~, D~LN~, NLR, and PLR for therapeutic effect and OS prediction. A two-tailed *P*-value ≤ 0.05 was considered statistically significant. Statistical analyses were performed using the Statistical Package for Social Sciences version 17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Patients and clinicopathological features
-----------------------------------------

A total of 87 male (73.1%) and 32 female (26.9%) patients were investigated. The median age was 63 years (range: 46--78). Primary tumors were located in the upper thoracic esophagus (Ut) in six patients (5.0%), in the Mt in 78 patients (65.5%), and in the lower thoracic esophagus (Lt) in 35 patients (29.5%). Single RT was administered to 32 patients; concurrent CRT was delivered to 87 patients. With a median follow-up time of 18 months (range: 4--36 months), 94 patients (79%) were dead at the end of follow-up time. The clinical and pathological characteristics of 119 patients are shown in [Table 1](#t1-cmar-10-217){ref-type="table"}.

Correlation between therapeutic efficacy and V~LN~, D~LN~, NLR, and PLR
-----------------------------------------------------------------------

A total of 119 patients with LNM after resection of esophageal carcinoma were grouped according to the median values of NLR, PLR, and the size of LNM, including V~LN~ and D~LN~, as shown in [Table 2](#t2-cmar-10-217){ref-type="table"}. The relationship between the responsiveness of treatment and these markers was analyzed by univariate logistic regression analysis. The results demonstrated that responses to treatment were highly associated with treatment method (*P*=0.011), NLR (*P*=0.000), PLR (*P*=0.003), V~LN~ (*P*=0.000), and D~LN~ (*P*=0.000). Next, multivariate logistic regression analysis showed that therapeutic method (HR=1.225, 95% CI: 1.085--2.837, *P*=0.032), NLR (HR=2.697, 95% CI: 1.201--7.429, *P*=0.019), and V~LN~ (HR=4.607, 95% CI: 1.124--18.889, *P*=0.034) were independent risk factors for tumor response.

Prognostic analysis based on NLR, PLR, V~LN~, and D~LN~
-------------------------------------------------------

For all patients, the median OS time was 16 months. The OS rates at the 1-, 2-, and 3-year period were 69.7%, 28.6%, and 21.1%, respectively. As shown in [Figure 1](#f1-cmar-10-217){ref-type="fig"}, in the NLR \< 3.33 group, the 1-, 2-, and 3-year OS rates were 79.7%, 45.5%, and 40.6%, respectively, while in the NLR ≥ 3.33 group, the OS rates were 60.4%, 11.8%, and 2.7%, respectively ([Figure 1A](#f1-cmar-10-217){ref-type="fig"}; *χ*^2^=27.298, *P*=0.000). In the PLR \< 154.24 group, the 1-, 2-, and 3-year OS rates were 80.0%, 40.0%, and 36.7%, respectively, and in the PLR ≥ 154.24 group, the OS rates were 59.3%, 16.9%, and 5.1%, respectively ([Figure 1B](#f1-cmar-10-217){ref-type="fig"}; *χ*^2^=16.719, *P*=0.000). In the V~LN~ \< 48.12 cm^3^ group, the 1-, 2, and 3-year OS rates were 88.1%, 50.8%, and 42.4%, respectively, while in the V~LN~ ≥ 48.12 cm^3^ group, the OS rates were 51.7%, 6.7%, and 1.8%, respectively ([Figure 1C](#f1-cmar-10-217){ref-type="fig"}; *χ*^2^=48.823, *P*=0.000). In addition, in the D~LN~ \< 4.61 cm group, the 1-, 2-, and 3-year OS rates were 84.7%, 52.5%, and 42.4%, respectively, while in the D~LN~ ≥ 4.61 cm group, the OS rates were 55.0%, 6.9%, and 1.6%, respectively ([Figure 1D](#f1-cmar-10-217){ref-type="fig"}; *χ*^2^=40.724, *P*=0.000).

[Figure 1](#f1-cmar-10-217){ref-type="fig"} shows the OS curves based on pretreatment NLR, PLR, V~LN~, and D~LN~. Our results indicated that NLR, PLR, V~LN~, D~LN~, and treatment methods were significantly associated with OS using the univariate analysis. Furthermore, multivariate Cox proportional hazard regression model analysis for OS was performed to identify the prognostic factors for enrolled patients treated with RT or CRT. The results showed that NLR, V~LN~, D~LN~, and therapeutic method were considered independent prognostic factors for OS, whereas PLR did not indicate a statistical difference associated with OS ([Table 3](#t3-cmar-10-217){ref-type="table"}).

ROC curve for therapeutic responsiveness and OS prediction
----------------------------------------------------------

ROC curves for therapeutic efficacy were plotted to verify the median values of NLR, PLR, V~LN~, and D~LN~ ([Figure 2](#f2-cmar-10-217){ref-type="fig"}). As shown in [Figure 2A](#f2-cmar-10-217){ref-type="fig"}, the area under the curve (AUC) for NLR, PLR, V~LN~, and D~LN~ was 0.709 (95% CI: 0.583--0.834, *P*=0.004), 0.636 (95% CI: 0.511--0.781, *P*=0.061), 0.668 (95% CI: 0.536--0.799, *P*=0.021), and 0.616 (95% CI*:* 0.511--0.781, *P*=0.051), respectively. The results indicated that NLR and V~LN~ were superior to PLR and D~LN~ as a predictive factor for therapeutic responsiveness in patients with LNM after resection of ESCC.

ROC curves for OS were also plotted, the AUC was 0.767 (95% CI: 0.650--0.884, *P*=0.001) for NLR, 0.633 (95% CI: 0.602--0.724, *P*=0.053) for PLR, 0.808 (95% CI: 0.712--0.904, *P*=0.000) for V~LN~, and 0.817 (95% CI*:* 0.723--0.910, *P*=0.000) for D~LN~, indicating that NLR, V~LN~, and D~LN~ were superior to PLR as a predictive factor for OS in patients with LNM after esophagectomy ([Figure 2B](#f2-cmar-10-217){ref-type="fig"}).

Correlations among the NLR and PLR, V~LN~, and D~LN~
----------------------------------------------------

As shown in [Figure 1](#f1-cmar-10-217){ref-type="fig"}, univariate analysis showed that a high NLR and PLR and a high V~LN~ and D~LN~ were all individually associated with an unfavorable survival outcome. Furthermore, the correlations between PLR and NLR and between V~LN~ and D~LN~ were examined using Pearson correlation analysis ([Figure 3](#f3-cmar-10-217){ref-type="fig"}). The results showed that there were moderate correlations between PLR and NLR and between V~LN~ and D~LN~ (correlation coefficient *R*^2^=0.493 and 0.572, respectively).

Discussion
==========

There are several clinical data supporting that the survival of cancer patient is determined not only by tumor itself but also by host-related factors, such as the systemic inflammatory status. In this clinical study, we investigated the significance for the tumor treatment response and survival prognosis of inflammatory markers and tumor burden-related index in patients with secondary LNM after resection of ESCC. This study indicated that NLR (*P*=0.019), treatment strategies (*P*=0.032), and V~LN~ (*P*=0.034) were independent risk factors for tumor treatment efficacy. While the NLR, V~LN~, and D~LN~ were considered independent prognostic factors for OS. To our knowledge, this is the first report to demonstrate the clinical significance of NLR, PLR, V~LN~, and D~LN~ in patients with LNM receiving CRT or RT after esophagectomy.

At present, surgery is the most important treatment strategy for patients with non-metastatic thoracic ESCC. However, the prognostic outcome is unsatisfactory, and the recurrence rate of ESCC is high after radical surgery. Liu et al[@b1-cmar-10-217] demonstrated that \~50% of patients with ESCC developed treatment failure during the follow-up period. Single-station LNM was the most common type of failure and the location of metastasis in the bilateral supraclavicular areas as well as the superior mediastinum was more frequent than in other regions. In the clinical practice, the OS rate of patients with locoregional recurrence was worse, and one of the reasons may consist of tumor volume affecting prognostic outcomes. One previous study demonstrated that larger GTV did predict a poorer prognosis in ESCC patients treated with radical radiochemotherapy.[@b4-cmar-10-217] A large tumor burden means more hypoxic cells, which is resistant to treatment, so the prognosis is worse. The negative impact of tumor hypoxia on survival is related to radiobiological mechanisms caused by hypoxia, which may include 1) the reduced oxygen enhancement effect, 2) increased radioresistance due to expression of genes for cell cycle delay and stress proteins, and/or 3) accelerated tumor progression to more radioresistant and metastatic variants by increased genetic heterogeneity.[@b19-cmar-10-217] In the present study, we determined that the GTV and maximum diameter of metastatic lymph nodes (V~LN~ and D~LN~) are useful for assessing the therapeutic effects and prognosis in ESCC patients with LNM after resection. The results found that patients who suffered the large tumor burden (V~LN~ ≥ 48.12 cm^3^ and D~LN~ ≥ 4.61 cm) had significantly worse therapeutic efficacy and OS than those who suffered small tumor burden (V~LN~ \< 48.12 cm^3^ and D~LN~ \< 4.61 cm).

In the case of hematological markers, a high NLR was significantly associated with poor response to treatment and unfavorable OS in patients with LNM after resection of ESCC. Since the pathologist Rudolf Virchow first discovered leukocytes in malignant tissue specimens \~150 years ago,[@b20-cmar-10-217] the prognostic values of pretreatment hematological markers have been highlighted. Currently, compelling evidence suggested that there were statistically significant differences in the therapeutic response and survival rates grouped by blood inflammatory markers for several types of malignancies.[@b10-cmar-10-217]--[@b15-cmar-10-217],[@b21-cmar-10-217],[@b22-cmar-10-217] Multiple studies have demonstrated that hyperfibrinogenemia and elevated NLR or the combination of NLR with PLR were the predictors of poor therapeutic response before initial treatment.[@b21-cmar-10-217],[@b22-cmar-10-217] Duan et al[@b23-cmar-10-217] reported that preoperative serum NLR is a useful prognostic marker to complement TNM staging for operable ESCC patients, particularly in patients with Stage IIIA disease. In clinical practice, variations in NLR and PLR can reflect changes in the relative number of neutrophils, platelets, and lymphocytes. Tumor cells can produce granulocyte colony-stimulating factor, tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, and IL-6, which can influence leukocyte and neutrophil counts in the bloodstream.[@b24-cmar-10-217] Some research also showed that platelets could enhance hematogenous metastasis by stabilizing tumor cell arrest in the vasculature, activating tumor cell proliferation, boosting tumor cell extravasation, and enhancing tumor cell interaction with the extracellular matrix.[@b25-cmar-10-217] In contrast, lymphocytopenia can also stimulate the release of suppressive immunological mediators, such as transforming growth factor-β (TGF-β) and IL-10, resulting in immunosuppression and consequently weakening of the lymphocyte functions.[@b26-cmar-10-217] Our univariate analysis suggested that the pretreatment NLR and PLR were independent risk factors for therapeutic responsiveness and OS in patients with LNM after esophagectomy. Furthermore, the multivariate analysis showed that only NLR \< 3.33 had significantly better therapeutic efficacy (HR=2.697, 95% CI: 1.201--7.429, *P*=0.019) and OS (HR=2.000, 95% CI: 1.127--3.548, *P*=0.018) than those who had NLR ≥ 3.33

This study has several potential limitations. First, concerning diagnostic criteria of LNM, the selection of enrolled patients mainly depended on positive CT scans instead of pathological biopsy during the observation period, which might have led to an inherent bias. Second, not all hemato-logical markers of inflammation were used in this analysis, because some biomarkers were not routinely examined, such as C-reactive protein[@b27-cmar-10-217],[@b28-cmar-10-217] and fibrinogen.[@b21-cmar-10-217] Third, it was a single-institution, retrospective study. Finally, 119 patients were enrolled in this study, and the sample size is small and may be insufficient to strengthen our results. Given these limitations, future larger randomized trials are needed to clarify these results.

Conclusion
==========

In summary, this study demonstrated that NLR and V~LN~ were promising as predictive markers for therapeutic effects, and NLR combined with V~LN~ and D~LN~ might be useful biomarkers in predicting outcomes in patients with LNM receiving CRT or single RT after esophagectomy. However, considering the retrospective nature of this study, large-scale prospective trials are still warranted to verify these results.
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![Kaplan--Meier curves for OS stratified according to NLR, PLR, V~LN~, and D~LN~ median values.\
**Notes:** (**A**) OS curves grouped by NLR median value (the 3-year OS for low NLR 40.7%, high NLR 2.7%; *P*=0.000). (**B**) OS curves stratified according to PLR median value (the 3-year OS for low PLR 36.7%, high PLR 5.1%; *P*=0.000). (**C**) OS curves stratified by V~LN~ median value (the 3-year OS for low V~LN~ 42.4%, high V~LN~ 1.80%; *P*=0.000). (**D**) OS curves grouped by D~LN~ median value (the 3-year OS for low D~LN~ 42.4%, high D~LN~ 1.60%; *P*=0.000). V~LN~, the GTV of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes\
**Abbreviations:** GTV, gross tumor volume; OS, overall survival; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.](cmar-10-217Fig1){#f1-cmar-10-217}

![The ROC curves grouped by NLR, PLR, V~LN~, and D~LN~.\
**Notes:** (**A**) ROC curves based on therapeutic effect. NLR is represented by the green line with an AUC=0.709; PLR is represented by the blue line with an AUC=0.636; V~LN~ is represented by the purple line with an AUC = 0.668; and D~LN~ is represented by the red line with an AUC=0.616. (**B**) ROC curves for OS. NLR is represented by the green line with an AUC=0.767; PLR is represented by the blue line with an AUC=0.633; V~LN~ is represented by the red line with an AUC=0.808; and D~LN~ is represented by the purple line with an AUC=0.817. V~LN~, the GTV of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes.\
**Abbreviations:** GTV, gross tumor volume; AUC, area under the curve; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; ROC: receiver operating characteristic.](cmar-10-217Fig2){#f2-cmar-10-217}

![Correlations among the prognostic markers.\
**Notes:** (**A**) Correlation chart between NLR and PLR (regression line: *Y*=1. 301+0.012´*X*, correlation coefficient: *R*^2^=0.493, *P*=0.000). (**B**) Correlation chart between V~LN~ and D~LN~ (regression line: *Y*= −36.990+21.731×*X*, correlation coefficient: *R*^2^=0.572, *P*=0.000). V~LN~, the GTV of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes.\
**Abbreviations:** GTV, gross tumor volume; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.](cmar-10-217Fig3){#f3-cmar-10-217}

###### 

Clinicopathological features of 119 patients with LNM after esophagectomy.

  Characteristics          Patients
  ------------------------ ------------------------
  Sex                      
   Male                    87 (73.1)
   Female                  32 (26.9)
  Age (years)              
   Mean ± SD               63.51±0.63
   Median (range)          63.00 (46--78)
  Primary tumor location   
   Upper                   6 (5.0)
   Middle                  78 (65.5)
   Lower                   35 (29.5)
  T classification         
   T1                      8 (6.7)
   T2                      43 (36.1)
   T3                      65 (54.6)
   T4                      3 (2.6)
  N classification         
   N0                      60 (50.4)
   N1                      43 (36.1)
   N2                      14 (11.8)
   N3                      2 (1.7)
  TNM stage                
   I                       6 (5.0)
   IIa                     29 (24.4)
   IIb                     33 (27.7)
   IIIa                    34 (28.6)
   IIIb                    17 (14.3)
  Location of LNM          
   Supraclavicular areas   44 (37.0)
   Mediastinum             75 (63.0)
  Treatment modalities     
   Radiotherapy only       32 (26.7)
   Chemoradiotherapy       87 (73.3)
  V~LN~, cm^3^             
   Mean ± SD               65.76±5.83
   Median (range)          48.12 (1.13--360.00)
  D~LN~, cm                
   Mean ± SD               4.80±0.19
   Median (range)          4.61 (1.27--10.83)
  NLR                      
   Mean ± SD               3.35±0.14
   Median (range)          3.33 (0.85--7.62)
  PLR                      
   Mean ± SD               170.20±7.73
   Median (range)          154.24 (50.70--541.43)

**Note:** V~LN~, the gross tumor volume of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes.

**Abbreviations:** LNM, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

###### 

Univariate and multivariate logistic regression analyses between tumor response and NLR, PLR, V~LN~, D~LN~ of 119 patients with LNM after resection of ESCC

  Factors                 Responder   Non-responder   Univariate analysis   Multivariate analysis                                   
  ----------------------- ----------- --------------- --------------------- ----------------------- ------- ------- --------------- -------
  Age, years                                                                                                                        
   \<63                   40          15              1.600                 0.334--3.490            0.238                           
   ≥63                    40          24                                                                                            
  Sex                                                                                                                               
   Male                   60          27              0.750                 0.321--1.751            0.506                           
   Female                 20          12                                                                                            
  Location of LNM                                                                                                                   
   Supraclavicular area   24          20              1.112                 0.538--2.967            0.856                           
   Mediastinum            56          19                                                                                            
  Treatment                                                                                                                         
   Chemoradiation         70          17              1.975                 1.184--3.958            0.011   1.225   1.085--2.837    0.032
   Radiation alone        10          22                                                                                            
  NLR                                                                                                                               
   ≥3.33                  31          29              4.584                 1.963--10.702           0.000   2.697   1.201--7.429    0.019
   \<3.33                 49          10                                                                                            
  PLR                                                                                                                               
   ≥154.24                32          27              3.375                 1.496--7.617            0.003   1.188   0.395--3.577    0.760
   \<154.24               48          12                                                                                            
  V~LN~                                                                                                                             
   ≥48.12 cm^3^           29          31              6.815                 2.768--16.779           0.000   4.607   1.124--18.889   0.034
   \<48.12 cm^3^          51          8                                                                                             
  D~LN~                                                                                                                             
   ≥4.61 cm               31          29              4.584                 1.963--10.702           0.000   1.087   0.277--4.267    0.905
   \<4.61 cm              49          10                                                                                            

**Note:** V~LN~, the gross tumor volume of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes.

**Abbreviations:** CI, confidence interval; LNM, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

###### 

Univariate and multivariate analyses of the NLR, PLR, V~LN~, and D~LN~ for the prediction of overall survival in patients with LNM after resection of ESCC (N=119)

  Factors           Univariate analysis   Multivariate analysis                                  
  ----------------- --------------------- ----------------------- ------- ------- -------------- -------
  Age               1.119                 0.746--1.680            0.586   --      --             --
  Sex               0.837                 0.537--1.303            0.430   --      --             --
  Location of LNM   1.009                 0.694--1.465            0.964   --      --             --
  Treatment         1.998                 1.395--2.988            0.011   1.223   1.119--2.998   0.048
  NLR               2.918                 1.895--4.492            0.000   2.000   1.127--3.548   0.018
  PLR               2.278                 1.500--3.458            0.000   0.992   0.559--1.762   0.979
  V~LN~             4.314                 2.740--6.792            0.000   2.379   1.149--4.923   0.020
  D~LN~             3.874                 2.455--6.112            0.000   2.901   1.489--5.652   0.002

**Note:** V~LN~, the gross tumor volume of metastatic lymph nodes; D~LN~, the maximum diameter of metastatic lymph nodes.

**Abbreviations:** CI, confidence interval; ESCC, esophageal squamous cell carcinoma; LNM, lymph node metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
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